-
1
-
-
0026028040
-
Rising incidence of adenocarcinoma of the esophagus and gastric cardia
-
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289
-
(1991)
JAMA
, vol.265
, pp. 1287-1289
-
-
Blot, W.J.1
Devesa, S.S.2
Kneller, R.W.3
Fraumeni Jr., J.F.4
-
2
-
-
0033853456
-
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries
-
Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645-654
-
(2000)
Int J Epidemiol
, vol.29
, pp. 645-654
-
-
Botterweck, A.A.1
Schouten, L.J.2
Volovics, A.3
Dorant, E.4
Van Den Brandt, P.A.5
-
3
-
-
13744258445
-
The role of overdiagnosis and reclassi-fication in the marked increase of esophageal adenocarcinoma incidence
-
Pohl H, Welch HG (2005) The role of overdiagnosis and reclassi-fication in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142-146
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 142-146
-
-
Pohl, H.1
Welch, H.G.2
-
4
-
-
23044493202
-
Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications
-
Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199-211
-
(2005)
Ann Intern Med
, vol.143
, pp. 199-211
-
-
Hampel, H.1
Abraham, N.S.2
El-Serag, H.B.3
-
5
-
-
33744732468
-
Body mass index and adenocarcinomas of the esophagus or gastric cardia: A systematic review and meta-analysis
-
Kubo A, Corley DA (2006) Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15:872-878
-
(2006)
Cancer Epidemiol Biomarkers Prev
, vol.15
, pp. 872-878
-
-
Kubo, A.1
Corley, D.A.2
-
6
-
-
0033580405
-
Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma
-
Lagergren J, Bergström R, Lindgren A, Nyrén O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma. N Engl J Med 340:825-831
-
(1999)
N Engl J Med
, vol.340
, pp. 825-831
-
-
Lagergren, J.1
Bergström, R.2
Lindgren, A.3
Nyrén, O.4
-
7
-
-
34347374560
-
How do we improve outcomes for gastric cancer?
-
Yeoh KG (2007) How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol 22:970-972
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 970-972
-
-
Yeoh, K.G.1
-
8
-
-
0038457443
-
Temporal trends (1973-1997) in survival of patients with esopha-geal adenocarcinoma in the United States: A glimmer of hope?
-
Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973-1997) in survival of patients with esopha-geal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627-1633
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1627-1633
-
-
Eloubeidi, M.A.1
Mason, A.C.2
Desmond, R.A.3
El-Serag, H.B.4
-
9
-
-
76749145878
-
Cancer of the stomach
-
De Vita VT et al eds, 8th edn. Lippincott Williams and Wilkins, Philadelphia
-
Pisters WTP, Kelsen DP, Tepper JE (2008) Cancer of the stomach. In: De Vita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1043-1079
-
(2008)
Cancer Principles and Practice of Oncology
, pp. 1043-1079
-
-
Pisters, W.T.P.1
Kelsen, D.P.2
Tepper, J.E.3
-
10
-
-
84861532120
-
Cancer of the esophagus
-
De Vita VT et al eds, 8th edn. Lippincott Williams and Wilkins, Philadelphia
-
Posner MC, Minsky BD, Ilson DH (2008) Cancer of the esophagus. In: De Vita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 993-1042
-
(2008)
Cancer Principles and Practice of Oncology
, pp. 993-1042
-
-
Posner, M.C.1
Minsky, B.D.2
Ilson, D.H.3
-
11
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
-
(2006)
J Clin Oncol
, vol.24
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
-
12
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
-
(2007)
Ann Oncol
, vol.18
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
-
13
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group
-
Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
-
(2006)
J Clin Oncol
, vol.24
, pp. 4991-4997
-
-
Van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
-
14
-
-
8044236424
-
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
-
Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
-
(1997)
Ann Oncol
, vol.8
, pp. 163-168
-
-
Glimelius, B.1
Ekstrom, K.2
Hoffman, K.3
-
15
-
-
42749101089
-
Chemotherapy for metastatic carcinoma of the esophagus and gastroesophageal junction
-
Homs MY, Gaast A, Siersema PD, et al (2006) Chemotherapy for metastatic carcinoma of the esophagus and gastroesophageal junction. Cochrane Database Syst Rev CD004063
-
(2006)
Cochrane Database Syst Rev
-
-
Homs, M.Y.1
Gaast, A.2
Siersema, P.D.3
-
16
-
-
0037089690
-
Epirubicin, cisplatin, and fluorouracil in gastric and oesophageal cancer: A step ahead?
-
Ilson DH (2002) Epirubicin, cisplatin, and fluorouracil in gastric and oesophageal cancer: a step ahead? J Clin Oncol 20:1962-1964
-
(2002)
J Clin Oncol
, vol.20
, pp. 1962-1964
-
-
Ilson, D.H.1
-
17
-
-
0242475354
-
Esophageal cancer: New developments in systemic therapy
-
Ilson DH (2003) Esophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525-532
-
(2003)
Cancer Treat Rev
, vol.29
, pp. 525-532
-
-
Ilson, D.H.1
-
18
-
-
33748412621
-
Cancer of the gastroesophageal junction: Current therapy options
-
Ilson DH (2006) Cancer of the gastroesophageal junction: current therapy options. Curr Treat Options in Oncol 7:410-423
-
(2006)
Curr Treat Options in Oncol
, vol.7
, pp. 410-423
-
-
Ilson, D.H.1
-
19
-
-
34548292026
-
Docetaxel, cisplatin, and fluorouracil in gastric cancer: Does the punishment fit the crime?
-
Ilson DH (2007) Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25:3188-3190
-
(2007)
J Clin Oncol
, vol.25
, pp. 3188-3190
-
-
Ilson, D.H.1
-
20
-
-
0034584740
-
Gastroesophageal junction adenocarcinoma
-
Swisher SG, Pisters PWT, Komaki R, Lahoti S, Ajani JA (2000) Gastroesophageal junction adenocarcinoma. Curr Treat Options in Oncol 1:387-398
-
(2000)
Curr Treat Options in Oncol
, vol.1
, pp. 387-398
-
-
Swisher, S.G.1
Pisters, P.W.T.2
Komaki, R.3
Lahoti, S.4
Ajani, J.A.5
-
21
-
-
33846629672
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarci-noma
-
Shah MA, Ramanathan RK, Ilson DH et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarci-noma. J Clin Oncol 24:5201-5206
-
(2006)
J Clin Oncol
, vol.24
, pp. 5201-5206
-
-
Shah, M.A.1
Ramanathan, R.K.2
Ilson, D.H.3
-
22
-
-
0742271770
-
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced esophageal and gastric carcinoma
-
Assersohn L, Brown G, Cunningham D et al (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced esophageal and gastric carcinoma. Ann Oncol 15:64-69
-
(2004)
Ann Oncol
, vol.15
, pp. 64-69
-
-
Assersohn, L.1
Brown, G.2
Cunningham, D.3
-
23
-
-
34250787547
-
Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer
-
Barone C, Basso M, Schinzari G et al (2007) Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 10:104-111
-
(2007)
Gastric Cancer
, vol.10
, pp. 104-111
-
-
Barone, C.1
Basso, M.2
Schinzari, G.3
-
24
-
-
38049047178
-
Capecitabine and oxaliplatin for advanced esophagogastric cancer
-
Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
-
(2008)
N Engl J Med
, vol.358
, pp. 36-46
-
-
Cunningham, D.1
Starling, N.2
Rao, S.3
-
25
-
-
38349183886
-
Expert opinion on management of gastric and gastro-oesophageal junction adeno-carcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group
-
Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adeno-carcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182-194
-
(2008)
Eur J Cancer
, vol.44
, pp. 182-194
-
-
Van Cutsem, E.1
Van De Velde, C.2
Roth, A.3
-
26
-
-
34147214716
-
Multiple molecular mechanisms for multidrug resistance transporters
-
Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-757
-
(2007)
Nature
, vol.446
, pp. 749-757
-
-
Higgins, C.F.1
-
27
-
-
31844448665
-
The translocation mechanism of P-glycoprotein
-
Callaghan R, Ford RC, Kerr ID (2006) The translocation mechanism of P-glycoprotein. FEBS Lett 580:1056-1063
-
(2006)
FEBS Lett
, vol.580
, pp. 1056-1063
-
-
Callaghan, R.1
Ford, R.C.2
Kerr, I.D.3
-
28
-
-
0348025526
-
Poloxamers
-
Rowe RC, Sheskey P, Weller PJ eds, American Pharmaceutical Association, Washington, DC
-
Collet JH (2003) Poloxamers. In: Rowe RC, Sheskey P, Weller PJ (eds) Handbook of pharmaceutical excipients. American Pharmaceutical Association, Washington, DC, pp 447-450
-
(2003)
Handbook of Pharmaceutical Excipients
, pp. 447-450
-
-
Collet, J.H.1
-
29
-
-
0032867434
-
Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
-
Alakhov V, Klinski E, Li S et al (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B: Biointerfaces 16:113-134
-
(1999)
Colloids Surf B: Biointerfaces
, vol.16
, pp. 113-134
-
-
Alakhov, V.1
Klinski, E.2
Li, S.3
-
30
-
-
0035556313
-
Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
-
Batrakova EV, Li S, Elmquist WF et al (2001) Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 85:1987-1997
-
(2001)
Br J Cancer
, vol.85
, pp. 1987-1997
-
-
Batrakova, E.V.1
Li, S.2
Elmquist, W.F.3
-
31
-
-
0029765581
-
Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells
-
Venne A, Li S, Mandeville R et al (1996) Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626-3629
-
(1996)
Cancer Res
, vol.56
, pp. 3626-3629
-
-
Venne, A.1
Li, S.2
Mandeville, R.3
-
32
-
-
33646348476
-
Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85
-
Batrakova EV, Kelly DL, Li S et al (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 3:113-123
-
(2006)
Mol Pharm
, vol.3
, pp. 113-123
-
-
Batrakova, E.V.1
Kelly, D.L.2
Li, S.3
-
33
-
-
17744382615
-
Effect of pluronic P85 on ATPase activity of drug efflux transporters
-
Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV (2004) Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226-2233
-
(2004)
Pharm Res
, vol.21
, pp. 2226-2233
-
-
Batrakova, E.V.1
Li, S.2
Li, Y.3
Alakhov, V.Y.4
Kabanov, A.V.5
-
34
-
-
1942470679
-
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
-
Danson S, Ferry D, Alakhov V et al (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085-2091
-
(2004)
Br J Cancer
, vol.90
, pp. 2085-2091
-
-
Danson, S.1
Ferry, D.2
Alakhov, V.3
-
35
-
-
50549174560
-
The determination of the number of patients required in a preliminary and a follow-up trial of a new chemo-therapeutic agent
-
Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemo-therapeutic agent. J Chronic Dis 13:346-353
-
(1961)
J Chronic Dis
, vol.13
, pp. 346-353
-
-
Gehan, E.A.1
-
36
-
-
0032921628
-
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial
-
Waters JS, Norman A, Cunningham D et al (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269-272
-
(1999)
Br J Cancer
, vol.80
, pp. 269-272
-
-
Waters, J.S.1
Norman, A.2
Cunningham, D.3
-
37
-
-
0031022803
-
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
-
Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
-
(1997)
J Clin Oncol
, vol.15
, pp. 261-267
-
-
Webb, A.1
Cunningham, D.2
Scarffe, J.H.3
-
38
-
-
33846419807
-
How can we best use structural information on P-glycoprotein to design inhibitors?
-
McDevitt CA, Callaghan R (2007) How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113:429-441
-
(2007)
Pharmacol Ther
, vol.113
, pp. 429-441
-
-
McDevitt, C.A.1
Callaghan, R.2
-
39
-
-
33745736603
-
Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment
-
Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859-1876
-
(2006)
Curr Med Chem
, vol.13
, pp. 1859-1876
-
-
Pérez-Tomás, R.1
-
40
-
-
33745746815
-
Pharmacological strategies for overcoming multidrug resistance
-
Nobili S, Landini I, Giglioni B et al (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861-879
-
(2006)
Curr Drug Targets
, vol.7
, pp. 861-879
-
-
Nobili, S.1
Landini, I.2
Giglioni, B.3
|